• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, October 26, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

Antibiotics developed in 1960s show promise for TB therapy

Bioengineer by Bioengineer
September 28, 2016
in Health
Reading Time: 2 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

First generation cephalosporins — antibiotics introduced as a treatment against bacterial infections in 1963 — now show promise for tuberculosis (TB) therapy, according to new research published in Scientific Reports.

Tuberculosis, caused by Mycobacterium tuberculosis, is the most deadly infectious disease in the world. Standard TB therapy takes at least six months and patients infected with multi-drug resistant (MDR) or extensively drug resistant (XDR) strains undergo treatments that are even longer (up to 24 months). Treatment is often associated with severe side effects. Studies indicate that the cost of developing a new drug has soared to $2.6 billion.

The in vitro study indicates cephalosporins work well on their own against bacteria that cause TB. But they are even more active when used in synergistic combinations with traditional and new TB therapies.

“Cephalosporins can be taken orally and have a good long-term safety record, but were never explored as a TB therapy,” says University of British Columbia (UBC) microbiologist Santiago Ramón-García, who led the study.

“While these are in vitro results, their potent anti-mycobacterial properties suggest cephalosporins could be used as part of new combinatorial TB therapies.”

“Because cephalosporins are already clinically approved drugs, they could be readily tested in the clinic,” says Prof. Charles Thompson from UBC who also led the work.

“New treatments are urgently needed to shorten the duration of the standard treatment and for MDR and XDR-TB therapy.”

The study was performed in collaboration with the Diseases of the Developing World GlaxoSmithKline Centre under an agreement with the Tres Cantos Open Lab Foundation. Grand Challenges Canada, Canadian Institute of Health Research, and British Columbia Lung Association provided initial support for the project.

Web Source: University of Faculty of Science British Columbia.

Journal Reference:

Santiago Ramón-García, Rubén González del Río, Angel Santos Villarejo, Gaye D. Sweet, Fraser Cunningham, David Barros, Lluís Ballell, Alfonso Mendoza-Losana, Santiago Ferrer-Bazaga, Charles J. Thompson. Repurposing clinically approved cephalosporins for tuberculosis therapy. Scientific Reports, 2016; 6: 34293 DOI: 10.1038/srep34293

The post Antibiotics developed in 1960s show promise for TB therapy appeared first on Scienmag.

Share12Tweet8Share2ShareShareShare2

Related Posts

Learning by Teaching Boosts Nursing Skills and Knowledge

October 26, 2025

Analyzing Respiratory Mask Fit with Simulations and Tests

October 26, 2025

Study Assesses Non-Invasive Support in Preterm Intubation

October 26, 2025

Linking Metabolism and Immunity in Dilated Cardiomyopathy

October 26, 2025
Please login to join discussion

POPULAR NEWS

  • Sperm MicroRNAs: Crucial Mediators of Paternal Exercise Capacity Transmission

    1284 shares
    Share 513 Tweet 321
  • Stinkbug Leg Organ Hosts Symbiotic Fungi That Protect Eggs from Parasitic Wasps

    310 shares
    Share 124 Tweet 78
  • ESMO 2025: mRNA COVID Vaccines Enhance Efficacy of Cancer Immunotherapy

    196 shares
    Share 78 Tweet 49
  • New Study Suggests ALS and MS May Stem from Common Environmental Factor

    134 shares
    Share 54 Tweet 34

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Learning by Teaching Boosts Nursing Skills and Knowledge

Analyzing Respiratory Mask Fit with Simulations and Tests

Study Assesses Non-Invasive Support in Preterm Intubation

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 67 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.